Cited by 66Cancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology ResearchMetabolism, Diabetes, and Cancer

COX6B2 drives metabolic reprogramming toward oxidative phosphorylation to promote metastasis in pancreatic ductal cancer cells

Open access
Nie, Ke, Li, Jin, He, Xujun, Wang, Yuqing, Zhao, Qiongya, Du, Miaomiao, Sun, Hongwei, Wang, Jinjing +3 more·2020·Oncogenesis

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer type with poor prognosis due to its high metastatic potential, however, the role of metabolic reprogramming in the metastasis of PDAC cell is not known. Here, we report that COX6B2 drive metastasis but not cancer cell proliferation in PDAC by enhancing oxidative phosphorylation function (OXPHOS). Transcriptome and clinical analyses revealed that cytochrome c oxidase subunit 6B2 (COX6B2) positively associated with metastasis of PDAC cells. Knockdown of COX6B2 in PDAC cells tuned down the assembly of complex IV and downregulated the function of OXPHOS, whereas re-expression of COX6B2 restored the function of OXPHOS and metastatic potential. Mechanistically, COX6B2 upregulated OXPHOS function to active purinergic receptor pathway for the metastasis of PDAC cells. Notably, the metastatic potential in PDAC could be reversely regulated by metformin, a drug was found accelerating the degradation of COX6B2 mRNA in this study. Collectively, our findings indicated that a complex metabolic control mechanism might be involved in achieving the balance of metabolic requirements for both growth and metastasis in PDAC, and regulation of the expression of COX6B2 could potentially encompass one of the targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41389-020-0231-2

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pancreatic ductal adenocarcinoma (PDAC) lines were chosen because cancers of the pancreas are characterized by rapid progression, invasiveness, and elevated fermentative metabolism.

    “Pancreatic ductal adenocarcinoma (PDAC) lines were chosen for our study because cancers of the pancreas are characterized by rapid progression,9,10 invasiveness,11,12 and elevated fermentative metabolism.13,14,15,16”

    From Dynamic IL-6R/STAT3 signaling leads to heterogeneity of metabolic phenotype in pancreatic ductal adenocarcinoma cells (2024) · cites this paper as [12]

    The Introduction describes PDAC as highly aggressive, with patients often dying within months, and attributes its aggressiveness partly to high metastatic potential. It reports both Warburg and anti-Warburg metabolism in PDAC, however, so it does not support characterizing pancreatic cancers generally by elevated fermentative metabolism. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nie, K., Li, J., He, X., Wang, Y., Zhao, Q., Du, M., Sun, H., Wang, J., Lyu, J., Fang, H., & Jin, L.
Affiliations
  • Wenzhou Medical University (CN)
  • Hangzhou Medical College (CN)
  • First Affiliated Hospital of Wenzhou Medical University (CN)
Corresponding author
  • Lyu, Jianxin
  • Fang, Hezhi
  • Jin, Liqin
Venue
Oncogenesis
Published
2020-05-15
Volume
9
Issue
5
Pages
51-51
ISSN
2157-9024 (ISSN-L)
OpenAlex
W3025982311
Cited by
64
References
41
Citations by year
2026: 7 · 2025: 11 · 2024: 7 · 2023: 13 · 2022: 10 · 2021: 10 · 2020: 6
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • Oncogenesis (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • the Key Discipline of Zhejiang Province in Medical Technology
  • Natural Science Foundation of Zhejiang Province (LY20H160012)
  • National Natural Science Foundation of China (81830071, 31670784)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
pancreatic ductal adenocarcinoma, metastasis, metabolic reprogramming, oxidative phosphorylation, metformin, mRNA degradation, tumor cell proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review